BioSpace News Archive

Ardelyx, Inc. today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a GI/Microbiome panel discussion at the Cowen 43rd Annual Health Care Conference on Monday March 6, 2023 at 9:10 A.M. Eastern Time in Boston, MA.

Elpiscience Biopharmaceuticals, Inc. today announced that the first patient has been dosed in a Phase 1 clinical trial of ES014, a first-in-class anti-CD39xTGF-β bispecific antibody (bsAb).

Cardiff Oncology, Inc. today announced that company management will participate in a corporate panel discussion and 1x1 investor meetings at the Cowen 43rd Annual Health Care Conference, which is taking place at the Boston Marriott Copley Place from March 6 – 8, 2023.

Agile Therapeutics, Inc. announced that it has received written notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC granting the Company’s request for a 180-day extension to regain compliance under Nasdaq Listing Rule 5550.

Genprex, Inc. announced it has entered into a securities purchase agreement with a single, healthcare-focused institutional investor for the purchase and sale of 3,809,524 shares of its common stock together with warrants to purchase up to 3,809,524 shares of common stock at a combined purchase price of $1.05 per share and accompanying warrant, pursuant to a registered direct offering.

Coagulant Therapeutics Corporation announced the online publication of a manuscript titled “Selective Modulation of Activated Protein C Activities by a Non-Active Site Targeting Nanobody Library” in the journal Blood Advances, a Journal of the American Society of Hematology.

Xlear has supplemented the numerous scientific studies it has already provided the Department of Justice and the Federal Trade Commission (FTC) in the government’s lawsuit against Xlear.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) today announced that Rhythm’s Netherlands subsidiary, Rhythm Pharmaceuticals Netherlands B.V. (“Rhythm BV”), acquired Xinvento B.V., a Netherlands-based biotech company focused on developing therapies for congenital hyperinsulinism (CHI).

Altamira Therapeutics Ltd. (Nasdaq:CYTO) today announced that it has filed a provisional patent application with the United States Patent and Trade Office (USPTO) to provide broad coverage of different KRAS mutations in human cancer treatment with nanoparticles comprising the Company’s OligoPhore™ platform and a single siRNA sequence.

Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the commercial launch of ELYXYBTM (celecoxib oral solution) in the U.S.